Working… Menu

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01403285
Recruitment Status : Terminated (Due to poor accrual. This decision was taken without any safety reasons. Since beginning of the study (June 2011) only six patients were enrolled.)
First Posted : July 27, 2011
Last Update Posted : May 19, 2014
National Cancer Institute (NCI)
Information provided by (Responsible Party):
immatics Biotechnologies GmbH

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014